Navigation Links
Brookhaven Lab and BioSET patent a synthetic peptide that enhances bone growth
Date:2/19/2009

UPTON, NY Brookhaven Science Associates, the company that operates and manages the U.S. Department of Energy's Brookhaven National Laboratory (BNL), and Biosurface Engineering Technologies, Inc. (BioSET), have been issued a U.S. patent on a synthetic peptide, called B2A.

"About 250,000 Americans undergo lumbar spine fusion surgeries each year to treat lower back pain," said Tom Rouche, BioSET President and CEO. "We have developed a novel combination medical device, called AMPLEX, that incorporates B2A osteo-inductive growth factor with an ultra-high grade ceramic bone substitute for use in this type of surgery. Preclinical studies have found that it is a safe and highly effective."

B2A enhances the effects of a tissue growth factor known as bone morphogenetic protein 2, or BMP-2. BMPs are a family of proteins in the human body responsible for the proliferation, repair and differentiation of cells in many tissues, including bone.

Brookhaven Lab scientist Louis Pea developed B2A with BioSET, and he performed the initial studies at Brookhaven. "I became interested in bone growth factors after NASA built a radiation research facility at Brookhaven," Pea said. "Weightlessness in space causes bone loss, and cosmic radiation can cause damage to cells, so I thought I might be able to study the interaction of the two. In setting up for that, I developed B2A and couldn't ignore its biomedical applications, so I focused on it instead. The ability to shift direction and follow promising leads is important in science, and I've had the freedom to do that at Brookhaven. I am gratified that BioSET has been able to take the B2A technology to a new level of clinical testing."

In recent preclinical studies, University of Iowa researchers used a rabbit model to evaluate AMPLEX spine fusion. They found that it enhanced the fusion, compared to a conventional surgical method that uses the rabbit's own pelvic bone to form the bone graft. Also, a t
'/>"/>

Contact: Diane Greenberg
greenb@bnl.gov
631-344-2347
DOE/Brookhaven National Laboratory
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Brookhaven scientists explore brains reaction to potent hallucinogen
2. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
3. Spectranetics to Appeal Decision in Patent Litigation
4. Patent Expiries of Proscar and Flomax/Harnal Will Cause a Significant Decline in Near-Term Sales of Benign Prostatic Hyperplasia Drugs
5. Actavis Confirms its Patent Challenge of Kings Avinza(R)
6. PartsSource Awarded US Patent for PartsFinder(TM) Application
7. Barr Confirms Patent Challenge of UROXATRAL(R)
8. Former Pfizer Patent Attorneys Join Brinks Hofer Gilson & Lione
9. VNUS Medicals Patent Lawsuit Against Laser Competitors to Proceed to Trial
10. Aida Granted Additional Anti-Cancer Patent
11. China Medicines ADTZ Project Has Been Selected as One of Six Patent Commercialization Projects in Guangdong Province
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... , ... July 07, 2015 , ... America is blessed ... California Casualty’s Nominate A Hero program offers a special way to say “thanks.” ... hero receives a $250 gift card and their place on the “Wall of Heroes.” ...
(Date:7/7/2015)... AURORA, Colo. (PRWEB) , ... ... ... healthcare landscape relies on highly educated and motivated leaders with strong managerial ... how well they clearly communicate with patients, staff, providers, business partners, insurance ...
(Date:7/7/2015)... Toronto, ON (PRWEB) , ... July 07, 2015 , ... ... which is effective immediately and permits the use of gluten-free claims for gluten free ... the prospect of expanding the Gluten-Free Certification Program (GFCP) to include gluten-free ...
(Date:7/7/2015)... ... July 07, 2015 , ... CSG ... have been selected by the Department of Vermont Health Access to provide Quality ... Information System (MMIS) and Integrated Contact Center System project. , Vermont is implementing ...
(Date:7/6/2015)... , ... July 06, 2015 , ... ... pre-clinical stages of drug discovery. iPSCs are generated from adult cells, such as ... any cell type in the human body. , iPSC-derived cardiomyocytes ...
Breaking Medicine News(10 mins):Health News:California Casualty Wants to Know: "Who Is Your Hero?" 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 2Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 3Health News:American Sentinel University Details Six Ways Healthcare Leaders Can Sharpen Communications Skills 4Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 2Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 3Health News:Holy Crap Plus Gluten Free Oats Is The First Product With Oats In Canada To Carry The Gluten-Free Certification Program Trademark 4Health News:CSG Government Solutions Selected by the Department of Vermont Health Access to Provide Quality Assurance and Independent Verification and Validation Services 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 2Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 3Health News:Cellular Dynamics’ Webinar Underscores the Value of Using Human iPSC-derived Cardiomyocytes for Investigative in vitro Drug Toxicology 4
... the damage to their lungs that exacerbates asthmatic symptoms just ... the University of Groningen in the Netherlands. The ... American Thoracic Society,s American Journal of Respiratory and Critical ... smoke appears to increase the thickness of the epithelium, or ...
... become a mainstay of multiple myeloma treatment may outperform ... who have received stem cell transplants from unrelated, partially ... be presented by Dana-Farber Cancer Institute investigators ... on Sunday, Dec. 6 (Abstract 48, Ernest N. Morial ...
... College of Wisconsin, in Milwaukee, found a substantial variation ... disease complications in children. Barriers to its use on ... identified. The study led by Amanda M. Brandow, ... College and Children,s Research Institute at the Children,s Hospital ...
... Hamilton, ON. Dec. 6, 2009 A new study provides ... as venous thromboembolism (VTE). The condition is estimated ... occurs when an abnormal clot forms in a vein and ... some cases, the clot may detach from its point of ...
... NEW ORLEANSA new three-drug combination has shown in a phase ... regimen" in the treatment of patients newly diagnosed with multiple ... say researchers from Dana-Farber Cancer Institute. Partial responses or ... with the drug combination in the multi-center study, with 74 ...
... , --In Youngest ... , PHILADELPHIA and NEW ORLEANS, Dec. 5 Pediatric ... with another gene to drive an often-fatal form of leukemia ... expect to better predict which infants may benefit from particular ...
Cached Medicine News:Health News:Quitting smoking can reverse asthma-inducing changes in lungs 2Health News:Bortezomib shows promise in reducing GVHD and reconstituting immune system in some patients 2Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:New drug shows promise for those with clotting disorders: McMaster researcher 2Health News:Multiple myeloma patients experience high response rate with new 3-drug combination 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4
(Date:7/6/2015)...  OrthoSpace Ltd. ("OrthoSpace" or "Company") announced today ... its US Investigational Device Exemption (IDE) pivotal study.  ... blinded control study that compares the Company,s InSpace ... repair for the treatment of full thickness massive ... available outside of the United States ...
(Date:7/6/2015)... , July 6, 2015 /CNW/ - The Canadian Pharmacists Association ... immunization strategy to ensure that all Canadians have the ... HPV (human papillomavirus) through immunization. The lack of access ... Canada is needlessly putting the health ... such as HPV, continue to pose a significant threat ...
(Date:7/6/2015)... 6, 2015 Mauna Kea ... multidisciplinary confocal laser endomicroscopy platform, announced today it ... Ministry of Health, Labor and Welfare (MHLW) ... the AQ-Flex 19 miniprobe.   Used ... miniprobe is comprised of a fiber-optic microscope that ...
Breaking Medicine Technology:OrthoSpace Enrolls First Patients in US IDE Study 2CPhA Calls for HPV Strategy for Young Men to Save Lives 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: